Autologous iPSC-derived RPE therapy (Beijing Tongren Hospital)

N/A

Report date: 2023/01/12 16:09:11

Base Information

Drug NameAutologous iPSC-derived RPE therapy (Beijing Tongren Hospital)
Drug Alias NameAutologous iPSC-derived RPEiPSC-RPEinduced pluripotent stem cell-derived retinal pigment epitheliumiPSC-RPE
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Tongren Hospital, Cmu
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Tongren Hospital, Cmu
Inactive CompaniesN/A
Active IndicationsMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A